Proton Pump Inhibitor Prescriptions and Subsequent Use in US Veterans Diagnosed with Gastroesophageal Reflux Disease

被引:23
|
作者
Gawron, Andrew J. [1 ,2 ,3 ]
Pandolfino, John E. [1 ]
Miskevics, Scott [3 ]
LaVela, Sherri L. [2 ,3 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Div Gastroenterol & Hepatol, Chicago, IL 60613 USA
[2] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL 60613 USA
[3] Edward Hines Jr VA Hosp, Dept Vet Affairs, Ctr Management Complex Chron Care, Hines, IL USA
基金
美国医疗保健研究与质量局;
关键词
drug; GERD; prescriptions; Veteran Health Affairs; RISK; ADHERENCE; THERAPY; MEDICATION; MAGNITUDE; FRACTURE; OVERUSE; IMPACT;
D O I
10.1007/s11606-013-2345-0
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Empiric proton pump inhibitor use is common for gastroesophageal reflux disease (GERD), but initial proton pump inhibitor (PPI) prescription patterns in Veterans are unknown. The study aims were to determine initial PPI prescriptions in Veterans diagnosed with GERD, and to characterize subsequent PPI use over the 2 years following initial prescription. We conducted a retrospective study using Veteran's Administration (VA) administrative data and chart review. Patients diagnosed with GERD and provided an initial PPI prescription at Hines VA Hospital from 2003 to 2007, with 2 year follow-up for each patient (through 2009). Initial PPI prescriptions were categorized as standard total daily dose or high total daily dose, and accuracy was confirmed by manual chart review. Descriptive statistics were calculated and bivariate analyses were used to assess for differences in demographics, prescriptions, and subsequent use by initial PPI dosage category. Of the 1,621 patients included in the study, 378 (23.3 %) had high total daily dose initial PPI prescriptions and 1,243 (76.7 %) patients had standard total daily dose initial prescriptions. The majority of patients (65.8 %) received a 90-day or greater initial prescription. Over the 2 years following the initial PPI prescription, 13.0 % of patients with initial standard daily dose prescriptions had evidence of step-up therapy. Only 7.1 % of patients with initial high daily dose PPI prescriptions had evidence of step-down therapy. A large majority of patients (83.8 %) had at least one refill over 2 years, and the overall medication possession ratio was 0.86. Many Veterans receive high total daily dose PPI prescriptions as initial therapy for a GERD diagnosis, and few patients have evidence for cessation or reduction of therapy. These results provide detailed data on prescribing and use of PPIs to help guide efforts for optimal PPI use in US Veterans.
引用
收藏
页码:930 / 937
页数:8
相关论文
共 50 条
  • [31] What are the precautions with proton pump inhibitor use for reflux disease?
    Mospan, Cortney M.
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2015, 28 (12): : 23 - 26
  • [32] Proton pump inhibitor therapy does not stop gastroesophageal reflux
    Zapata, Carlos
    Sharma, Neeraj
    Castell, Donald
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S23 - S24
  • [33] Role of Acid and Weakly Acidic Reflux in Gastroesophageal Reflux Disease Off Proton Pump Inhibitor Therapy
    Sung, Hea Jung
    Cho, Yu Kyung
    Moon, Sung Jin
    Kim, Jin Su
    Lim, Chul Hyun
    Park, Jae Myung
    Lee, In Seok
    Kim, Sang Woo
    Choi, Myung-Gye
    JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2012, 18 (03) : 291 - 297
  • [34] Prospective Evaluation of Duodenogastroesophageal Reflux in Gastroesophageal Reflux Disease Patients Refractory to Proton Pump Inhibitor Therapy
    Kunsch, S.
    Neesse, A.
    Linhart, T.
    Nell, C.
    Gress, T. M.
    Ellenrieder, V.
    DIGESTION, 2012, 86 (04) : 315 - 322
  • [35] RISK OF PNEUMONIA ASSOCIATED WITH PROTON PUMP INHIBITOR USE AMONG COMMUNITY DWELLING ADULTS WITH GASTROESOPHAGEAL REFLUX DISEASE
    Rane, P.
    Guha, S.
    Garey, K.
    Chen, H.
    Johnson, M. L.
    Aparasu, R. R.
    VALUE IN HEALTH, 2017, 20 (05) : A179 - A180
  • [36] The Impact of Gastroesophageal Reflux Disease and Proton Pump Inhibitor Use on the Risk of Repeat Catheter Ablation for Atrial Fibrillation
    Cai, Jennifer X.
    Algara, Miguel
    Lo, Wai-Kit
    Kapur, Sunil
    Chan, Walter W.
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2024, 15 (06)
  • [37] Weight Loss Is Truly Effective in Reducing Symptoms and Proton Pump Inhibitor Use in Patients With Gastroesophageal Reflux Disease
    De Bortoli, Nicola
    Tolone, Salvatore
    Savarino, Edoardo V.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (11) : 2023 - 2023
  • [38] Additional Mosapride to Proton Pump Inhibitor for Gastroesophageal Reflux Disease: A Meta-Analysis
    Nishizawa, Toshihiro
    Mori, Kiyoto
    Yoshida, Shuntaro
    Ebinuma, Hirotoshi
    Toyoshima, Osamu
    Suzuki, Hidekazu
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (09) : 1 - 11
  • [39] Work productivity and response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease
    Wahlqvist, Peter
    Ducrotte, Philippe
    Jones, Roger
    Liker, Harley
    GASTROENTEROLOGY, 2007, 132 (04) : A350 - A350
  • [40] Proton pump inhibitor improves breath marker in moderate asthma with gastroesophageal reflux disease
    Shimizu, Yasuo
    Dobashi, Kunio
    Zhao, Jian Jun
    Kawata, Tadayoshi
    Ono, Akihiro
    Yanagitani, Noriko
    Kaira, Kyoichi
    Utsugi, Mitsuyoshi
    Hisada, Takeshi
    Ishizuka, Tamotsu
    Mori, Masatomo
    RESPIRATION, 2007, 74 (05) : 558 - 564